We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+27.7%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.4B
AUM Growth
+$1.73B
Cap. Flow
-$958M
Cap. Flow %
-5.21%
Top 10 Hldgs %
90.4%
Holding
118
New
7
Increased
23
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$60.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$35.8M
3
ROIV icon
Roivant Sciences
ROIV
+$33.4M
4
KYNB
Kyntra Bio
KYNB
+$26.7M
5
BPMC
Blueprint Medicines
BPMC
+$15M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$605M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$395M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$110M
4
TVTX icon
Travere Therapeutics
TVTX
+$25.8M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMMT icon
51
Summit Therapeutics
SMMT
$10.2B
$11M 0.06%
6,304,705
+4,304,705
+215% +$11.7M
ADAP
52
DELISTED
Adaptimmune Therapeutics
ADAP
$10.7M 0.06%
9,830,877
– –
OPT
53
DELISTED
Opthea Limited American Depositary Shares
OPT
$10.6M 0.06%
2,691,391
– –
VSTM icon
54
Verastem
VSTM
$528M
$10.6M 0.06%
2,126,787
-122,288
-5% -$774K
FATE icon
55
Fate Therapeutics
FATE
$275M
$9.53M 0.05%
1,671,717
+1,456,022
+675% +$8.79M
PNT
56
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.5M 0.05%
1,169,103
– –
BLUE
57
DELISTED
bluebird bio
BLUE
$7.95M 0.04%
124,986
– –
ALLO icon
58
Allogene Therapeutics
ALLO
$625M
$7.79M 0.04%
+1,576,901
New +$10.1M
MRSN
59
DELISTED
Mersana Therapeutics
MRSN
$7.75M 0.04%
+75,445
New +$10.6M
WHWK
60
Whitehawk Therapeutics
WHWK
$181M
$7.17M 0.04%
989,928
– –
SERA icon
61
Sera Prognostics
SERA
$80.3M
$6.85M 0.04%
1,789,000
+1,587,438
+788% +$4.17M
GERN icon
62
Geron
GERN
$898M
$6.64M 0.04%
+3,061,224
New +$8.69M
SANA icon
63
Sana Biotechnology
SANA
$882M
$6.54M 0.04%
+2,000,000
New +$7.99M
ARAV
64
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.52M 0.04%
3,261,224
– –
MGNX icon
65
MacroGenics
MGNX
$233M
$6.4M 0.03%
892,579
– –
ALEC icon
66
Alector
ALEC
$169M
$5.97M 0.03%
964,851
+282,860
+41% +$2.3M
LONA
67
LeonaBio Inc
LONA
$66.1M
$5.88M 0.03%
235,036
+47,052
+25% +$1.52M
INSM icon
68
Insmed
INSM
$22.4B
$5.85M 0.03%
343,000
+323,050
+1,619% +$6.28M
TCRX icon
69
TScan Therapeutics
TCRX
$48.5M
$5.85M 0.03%
2,784,792
– –
NTRA icon
70
Natera
NTRA
$36.4B
$5.55M 0.03%
100,000
– –
CMPX icon
71
Compass Therapeutics
CMPX
$349M
$5.09M 0.03%
1,557,630
– –
AFMD
72
DELISTED
Affimed
AFMD
$4.92M 0.03%
659,683
– –
RLAY icon
73
Relay Therapeutics
RLAY
$4B
$4.68M 0.03%
+284,000
New +$5.09M
BCEL
74
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.03M 0.02%
3,532,760
– –
IPSC icon
75
Century Therapeutics
IPSC
$364M
$3.99M 0.02%
1,149,340
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Baker Bros. Advisors held 118 positions worth $18.4B, up 10% from $16.7B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors withdrew a net $958M in Q1 2023, closing 13 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $605M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Blueprint Medicines worth $15M.

  • Baker Bros. Advisors's largest Q1 2023 buy was Blueprint Medicines: 333,665 shares worth $15M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2023, an estimated $60.8M increase.
  • Baker Bros. Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $395M.
  • Baker Bros. Advisors fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $605M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $18.4B portfolio in Q1 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 13 in Q1 2023.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $18.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.